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Chronic left ventricular (LV) pressure overload states, as
seen in long-standing systemic arterial hypertension or LV
outflow tract obstruction, are well tolerated for many years.
In such pathophysiologic circumstances, an increase in the
ratio of LV wall thickness to chamber radius mitigates, but
does not necessarily fully normalize, the afterload or forces
against which the myocardium shortens during systole (1,2).
Although beneficial, this adaptive response, also known as
concentric hypertrophy, may also cause a reduction in LV
chamber distensibility and, in some instances, an increase in
the elastic stiffness of the myocardium (3–5). With extended
passage of time the increased afterload imposed by hyper-
tension or LV outflow obstruction outstrips all salutary
adaptive mechanisms, preload reserve becomes exhausted
despite LV chamber dilation and basal contractility becomes
mismatched to the level of afterload, provoking a lower
extent and speed of shortening of the LV chamber (6).
Concomitant elevation of both the LV end-diastolic pres-
sure and left atrial mean pressure gives rise to pulmonary
capillary and alveolar congestion, whereas reduced systolic
fractional shortening is associated with an inadequate car-
diac output either at rest or with exercise. The patient with
a pressure overload condition is then exhibiting the clinical
syndrome of congestive heart failure (CHF).
See page 664
VENTRICULAR REMODELING
IN PRESSURE OVERLOAD STATES
Though this traditional biomechanical construct of the
pathophysiology of pressure overload hypertrophy has va-
lidity, it fails today to capture fully the much broader
adaptations (genetic, molecular, neurohormonal) that are
known to accompany the development of ventricular dila-
tion, and other clinical manifestations of heart failure, in
diseases associated with pressure overload hypertrophy.
These latter changes have come to be known as “cardiac
remodeling,” a term that, at first reception, connotes gross
pathoanatomic change but which, by extended definition,
encompasses a host of alterations in homeostatic mecha-
nisms (endocrine, autocrine and paracrine) that, under
normal conditions, control vascular tone, blood volume,
basal contractile state, programmed cell death (apoptosis),
as well as the architectural integrity and organization of
myocardial sarcomeres (7–10).
These homeostatic mechanisms, like concentric hypertro-
phy, can be considered protective and reparative but also
detrimental (11). With sustained pressure overload, exper-
imental and clinical evidence shows that tissue heterogene-
ity develops with an imbalance struck between the muscular
and nonmuscular components of the myocardium. Scarring
replaces necrotic myocytes, and a reactive fibrosis is ob-
served in the interstitium and perivascular areas. Hypertro-
phy and hyperplasia of vascular smooth cells lead to medial
thickening and loss of coronary arteriolar vasodilator re-
serve. Associated with these changes, the left ventricle
dilates, myocardial contractility may be either normal or
diminished (2,12–15), diastolic chamber stiffness is variably
normal or decreased (3–5) and myocardial stiffness may be
variably normal or increased (3–5). What seems indisput-
able is that in humans we witness an augmented incidence
of CHF, arrhythmias and coronary events (16).
RELATIVE PATHOGENIC ROLES OF MYOCARDIAL
CONTRACTILITY AND CARDIAC REMODELING
It is within this broader construct of the natural history of
pressure overload hypertrophy that the question has been
posed: “How important is reduced contractility itself, as
opposed to other effects of cardiac remodeling, in the
manifestations of CHF?” In this issue of the Journal, Norton
et al. (17) report on their pursuit of this question in a rat
model of pressure overload hypertrophy created by suprare-
nal artery banding. Approximately one-half of the pressure
overload hypertrophy animals studied developed manifesta-
tions of CHF (POH-F group), with lung edema, significant
LV chamber dilation and a nonsignificant increase in wall
thickness compared to control rats. The other one-half
showed concentric myocardial hypertrophy in response to
the pressure overload, but no evidence of LV chamber
dilation or an increase in their lung weight to body weight
ratio (POH-NF group). Compared to controls, both POH
groups showed reduction in myocardial contractility when
assessed by ex vivo end-systolic stress-strain relations; by
contrast, the in vivo systolic myocardial end-systolic myo-
cardial stiffness analysis failed to detect a depression of
myocardial contractility. The in vivo stress-shortening rela-
tions suggested a small and equivalent decrement in the two
POH groups, compared to controls. Despite this essential
equivalency of myocardial contractility, whether normal or
depressed, only the POH-F group manifested ventricular
dilation, wall thinning and lung edema, leading the inves-
tigators to conclude that CHF was dependent “primarily”
upon the processes of remodeling.
It is important to recognize that CHF could not be
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attributed solely and categorically to one pathogenetic
mechanism as opposed to the other. Although there is
inconsistency between the in vivo and ex vivo systolic
stiffness analyses, some reduction in contractility appeared
to be operative in both groups, a conclusion shared by the
investigators (17). This depression may be time-dependent
and witnessed only if the offending disease process has been
operative for a sufficient period of time. For example, in the
Mirsky et al. study (3) of the evolution of LV dysfunction in
the spontaneously hypertensive rat (SHR), the ejection
fraction-afterload relations of 6- and 12-month-old rats
were similar to those of normotensive rats of all ages;
however, a depression in contractile state of the SHR group
occurred at 18 months and was further depressed at 24
months (3). Importantly, this depression of contractile state
was evident before the left ventricle dilated and before any
deterioration of cardiac performance was witnessed.
The adequacy of the Norton et al. (17) approach to
detection of depressed myocardial contractility should also
be examined. An acute upward or downward shift in the
position and slope of the end-systolic pressure-dimension
relation is relatively well accepted as reliable measures of
acute enhancement or declination of contractility, respec-
tively. Nevertheless, because of the important influence of
intrinsic ventricular size (or chamber remodeling based
upon increased sarcomeres laid down in series) on the
pressure-diameter or pressure-volume relation, most inves-
tigators in the field now analyze myocardial contractility by
an end-systolic force-normalized dimension relation.
Myocardial stiffness, calculated from the stiffness con-
stant of the mid-wall stress-strain relation, is particularly
appealing for overcoming the confounding effects of cham-
ber size (18). Use of this construct would seem particularly
important in an experimental or clinical investigation where
chamber remodeling is occurring. Thus, the finding that
end-systolic myocardial stiffness was equivalent in both
POH groups, despite significant dilation only in those
showing CHF, appears supportable. It leaves open the
question, however, of why the in vivo and ex vivo end-
systolic analyses were not consistent.
Contractility was also assessed in the Norton et al. study
(17) by examining the mid-wall fractional shortening-stress
relation and comparing groups at an end-systolic iso-stress
of 75 gcm2. The slopes of the regression lines of these
relations in both POH groups showed an equivalent ten-
dency to depression compared to the control group. By
statistical analysis, however, no significant differences ex-
isted among all three groups. Some sensitivity for detection
of depressed contractility may have been lost by analysis of
only end-systolic stress as the measure of afterload. Al-
though end-systolic stress can be rationally construed as the
force that ultimately ends ventricular shortening, it does not
quantitate the average forces that resist shortening through-
out systole. Determination of mean ejection stress would
more properly provide this measure (19).
It is important to recognize that there was no third POH
group that manifested CHF while exhibiting manifestations
of cardiac remodeling and unequivocally normal contractil-
ity. Thus, I believe one would have to conclude that it is the
combination of both pathogenetic processes that ultimately
leads to the syndrome of CHF in sustained pressure
overload hypertrophy.
Role of diastolic dysfunction in CHF. It does not appear
that alterations in the diastolic properties of the left ventricle
contributed to the development of pulmonary congestion in
the POH-F group. Nevertheless, we do not have available
in these experiments measurements of LV end-diastolic
pressure, pulmonary capillary wedge pressures or in vivo LV
diastolic stiffness parameters. The investigators (17) did
analyze ex vivo diastolic stiffness of the POH-NF versus the
POH-F groups and found that there was a trend toward a
more compliant pressure-volume curve (reduced exponen-
tial chamber stiffness constant) in the POH-F group. The
ex vivo myocardial stiffness constant did not differ signifi-
cantly among the control, POH-NF and POH-F groups.
ACUTENESS AND DURATION OF
PRESSURE OVERLOAD: EFFECTS ON
MYOCARDIAL CONTRACTILITY AND REMODELING
The experiment by Norton et al. (17) represents the analysis
of an acutely imposed pressure overload, extending out to 20
weeks, at which time the animals were sacrificed. This is not
equivalent to the slowly developing pressure overload of
human hypertension or aortic valve obstruction imposed
over many years. There was no serial evaluation of LV
function between the time of imposition of the suprarenal
band and the evaluation presacrifice at 20 weeks. Thus, we
do not know whether the POH-F group manifested heart
failure because of the adverse consequences of remodeling or
the failure to develop adequate hypertrophy.
Conversely, we do not know whether a longer period of
observation might have uncovered more definitive signs of
reduced contractility and CHF in a higher proportion of
rats. Other experimental studies where an acute pressure
overload has been applied have shown an initial phase where
the heart dilates with invocation of preload reserve, the
ventricular wall thins, wall stress acutely augments and
myocardial shortening significantly declines (both an acute
afterload excess and reduction of myocardial contractility)—
point A to point B in Figure 1 (2,20,21). As concentric
hypertrophy develops, cavity dilation diminishes, wall stress
is lessened, myocardial shortening improves and the ventri-
cle is once again operating on its original force-velocity
curve—point B to point C in Figure 1. Then, as adverse
remodeling develops, the ventricle again begins to dilate,
invoking the residual preload reserve, LV shortening again
diminishes and wall stress (no longer fully compensated)
augments—points C to D in Figure 1. However, it is
conceivable that the transition between points B and C did
not occur at all in the POH-F rats and an inadequate
amount of hypertrophy developed—points B to D in Figure 1.
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Such a phenomenon was noted by Tagawa et al. (20) in a
dog model of aortic stenosis studied over a period of eight
weeks. Dogs with hypertrophy alone had a very substantial
increase in LV mass and preservation of a normal ejection
and mean systolic wall stress. Dogs with hypertrophy and
associated failure had a substantial but lesser increase in LV
mass and a reduction in ejection fraction, as well as a marked
increase in mean systolic wall stress (20).
More recently, published serial observations in a pig
pressure overload model suggested that the early period of
LV dilation and reduced myocardial contractility lasts ap-
proximately 12 h, with a relatively broad standard deviation
at that point as to the recovery of ventricular shortening
(21). It appears, nevertheless, that most pressure overload
experimental models pass through a period of compensated
concentric hypertrophy before showing signs of CHF. As
noted above, the duration of a pressure overload state, as
shown in the Mirsky et al. (3) experiment, undoubtedly
influences the development of depressed myocardial con-
tractility.
MOLECULAR MECHANISMS THAT
UNDERLIE ADVERSE REMODELING
If adverse remodeling is ultimately the “Achilles’ heel” of
pressure overload hypertrophy, what are the molecular
mechanisms that underlie both the development of concen-
tric hypertrophy and the transition from the compensated to
the decompensated state? Evidence that bears on this
question continues to accumulate rapidly. In the late 1980s
and early 1990s it was shown that the pathologic hypertro-
phy of mechanically overloaded hearts was associated with
changes in gene and protein expression that reprised that of
the fetal heart (22,23). Further evidence developed that
pressure overload hypertrophy is induced by a number of
candidate signaling pathways involving humoral growth
factors (angiotensin II, endothelin-1, insulin-like growth
factor-I), inhibition of pathways of apoptosis of myocytes
(gp130 ligands), catecholamines, associated G proteins and
downstream kinase effectors (8,24). The latter signaling
molecules include protein kinase C, tyrosine kinases, the
mitogen-activated protein kinase family, Ras, and the Janus
kinase/signal transducer and activator of transcription family.
Also, Ca2 has been shown to be an important second
messenger in cell growth and survival. In response to growth
stimuli, cytosolic Ca2 increases, and calcincurin, a ubiqui-
tous phosphatase, is activated, resulting in dephosphoryla-
tion of a class of transcription factors (nuclear factors of
activated T cells), which then regulate expression of specific
genes. Although controversial, calcineurin appears to be a
requisite mediator of myocardial hypertrophy (25–27). If
calcineurin inhibitory proteins are transgenically expressed
in the mouse heart, concentric hypertrophy secondary to
abdominal aorta-banding or long-term infusion of the
-adrenergic agonist isoproterenol is significantly inhibited.
Moreover, adenoviral Cain (a calcineurin inhibitor) has
been used to transfect the myocardium before aortic band-
ing. Seven days later, pressure overload hypertrophy was
found to be diminished by 40%. These experiments suggest
that calcineurin plays a critical role in the hypertrophic
response to pressure overload. Nevertheless, essentially
complete inhibition of calcineurin served to attenuate but
not completely prevent concentric hypertrophy, suggesting
that redundant signaling pathways exist.
Figure 1. Conceptual construct of afterload-shortening relations of left ventricle in normal or control (A), acute pressure overload (B), chronic pressure
overload with concentric hypertrophy (C) and decompensated congestive heart failure (D) stages of experimental models of pressure overload hypertrophy.
See text for discussion.
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Although the molecular mechanisms behind the devel-
opment of concentric hypertrophy are progressively forth-
coming, the correlates of the transition from a compensated
to a decompensated pressure overload state are less well
defined. One promising finding, now reported in both
animal models and man, is increased microtubule compo-
nent of the extramyofilament cytoskeleton. Upregulation of
-tubulin and -tubulin, the major microtubule proteins,
persists during prolonged, compensated right ventricular
pressure overload hypertrophy and also after the develop-
ment of right ventricular failure (20). It has been shown that
this increased density of microtubule network imposes an
increased viscous load on the shortening sarcomeres during
contraction, a finding that can be reversed by depolymer-
ization of the microtubules. Recently, in this Journal, Zile et
al. (19) reported that patients undergoing aortic valve
replacement for aortic stenosis exhibited a markedly aug-
mented microtubule protein in biopsy specimens in those
individuals with borderline or overtly abnormal LV short-
ening.
FUTURE DIRECTIONS OF RESEARCH
The observations by Norton et al. (17) provide further
impetus to research efforts aimed at unraveling the complex
mechanisms behind “cardiac remodeling” and, in particular,
the transition to CHF in pressure overload hypertrophy
states. Once molecular biological correlates of the transition
to heart failure are better understood, investigation of their
inhibition and reversibility will be required. Only then will
clinical cardiologists move beyond the laudable improve-
ments in treatment of CHF of pressure overload hypertro-
phy that were formulated in the twentieth century. It is
hoped we will have a rationale for more than manipulating
loading conditions, enhancing contractility, and correcting
mechanical defects of cardiac function.
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